{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T01:25:57Z","timestamp":1790040357602,"version":"4.0.1"},"reference-count":25,"publisher":"SAGE Publications","issue":"5","license":[{"start":{"date-parts":[[2025,1,17]],"date-time":"2025-01-17T00:00:00Z","timestamp":1737072000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Oncol Pharm Pract"],"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Sinusoidal obstructive syndrome (SOS)\/veno-occlusive disease (VOD) is a serious complication in hematopoietic stem-cell transplant (HSCT) patients. Gemtuzumab-ozogamicin (GO) and InO are known to cause SOS\/VOD in leukemic and transplant populations. Due to limited data on ursodiol prophylaxis in non-HSCT patients, we aimed to assess hepatotoxicity, SOS\/VOD incidences, time to hepatotoxicity, and confirmed SOS\/VOD in adults receiving GO or InO\u2009\u00b1\u2009ursodiol.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A multicenter, retrospective chart review of adult acute leukemia patients who received \u22651 dose of GO or InO at DFCI\/some of the Harvard Cancer Centers during 4-year period (9\/1\/2017\u20139\/1\/2021). Acute promyelocytic leukemia patients and post-GO or InO HSCT-recipients (100-day follow-up period) were excluded. Descriptive summaries are provided, direct comparisons were made using Student T-test (continuous variables) and Fisher's exact test (categorical variables).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In our population (N\u2009=\u200982), 87.8% received ursodiol and 12.2% did not. There were no significant differences in baseline to peak hepatic labs. The No-Ursodiol Group had higher incidence of Grade 3 aspartate aminotransferase (AST) transaminitis vs. the Ursodiol Group (60% vs. 20.8%; p\u2009=\u20090.015), and a trend towards shorter mean time to Grade 3 AST transaminitis (18.5 vs. 23.8 days; p\u2009=\u20090.30). Moreover, 4.2% of Ursodiol Group developed SOS\/VOD vs. 0% in the No-Ursodiol Group (NS). Three patients developed SOS\/VOD: 2 received GO, 1 received InO, and 2 were alive by the end of the follow-up period.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In our cohort, ursodiol prophylaxis in adults receiving GO\/InO is not associated with lower incidences of hepatotoxicity, SOS\/VOD, or time to Grade 3 AST transaminitis, but is associated with decreased incidence of AST elevations.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10781552241313473","type":"journal-article","created":{"date-parts":[[2025,1,17]],"date-time":"2025-01-17T10:39:34Z","timestamp":1737110374000},"page":"803-810","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":2,"title":["Utility of ursodiol prophylaxis against sinusoidal obstruction syndrome (SOS)\/ veno-occlusive disease (VOD) in acute leukemia patients receiving gemtuzumab-ozogamicin (GO) or inotuzumab-ozogamicin (InO)"],"prefix":"10.1177","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-7990-8100","authenticated-orcid":false,"given":"Grace","family":"Mosallam","sequence":"first","affiliation":[{"name":"Massachusetts College of Pharmacy and Health Sciences School of Pharmacy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric S","family":"Winer","sequence":"additional","affiliation":[{"name":"Dana-Farber Cancer Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia H","family":"Keating","sequence":"additional","affiliation":[{"name":"Dana-Farber Cancer Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yael","family":"Flamand","sequence":"additional","affiliation":[{"name":"Dana-Farber Cancer Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loriel J","family":"Solodokin","sequence":"additional","affiliation":[{"name":"Massachusetts College of Pharmacy and Health Sciences School of Pharmacy"},{"name":"Dana-Farber Cancer Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,1,17]]},"reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1177\/20503121211034366"},{"key":"e_1_3_2_3_2","unstructured":"National Cancer Institute. SEER cancer statistics review. https:\/\/seer.cancer.gov\/\/ (accessed 29 January 2023)."},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.13.3244"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1509277"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2006.07.005"},{"key":"e_1_3_2_7_2","unstructured":"Gemtuzumab ozogamicin. In: Lexi-Drugs. Lexi-Comp https:\/\/onlinelexicom.ezproxymcp.flo.org\/lco\/action\/doc\/retrieve\/docid\/patch_f\/6975?cesid=3FVtmQ8aze0&amp;searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3Dgemtuzumab%26t%3 Dname%26va%3Dgemtuzumab (2021 accessed 30 August 2021)."},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00489"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-020-00975-2"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-09-797712"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)60485-1"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2018.188888"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.28136"},{"key":"e_1_3_2_14_2","unstructured":"Inotuzumab ozogamicin. In: Lexi-Drugs. Lexi-Comp https:\/\/onlinelexicom.ezproxymcp.flo.org\/lco\/action\/doc\/retrieve\/docid\/patch_f\/6532654cesid=8WT8oy4Q1Wy&amp;searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3Dinotu zumab%26t%3Dname%26va%3Dinotuzumab (2021 accessed 30 August 2021)."},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2019.02.018"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.37120"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-01-762419"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2001-12-0159"},{"key":"e_1_3_2_19_2","first-page":"757","article-title":"The nomenclature, definition and distinction of types of shock","volume":"115","author":"Standl T","year":"2018","unstructured":"Standl T, Annecke T, Cascorbi I, et al. The nomenclature, definition and distinction of types of shock. Dtsch Arztebl Int 2018; 115: 757\u2013768.","journal-title":"Dtsch Arztebl Int"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-128-12_Part_1-199806150-00002"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1096-8652(200005)64:1<32::AID-AJH6>3.0.CO;2-N"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2006.09.012"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12558"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-019-0705-z"},{"key":"e_1_3_2_25_2","unstructured":"U.S. Department of Health and Human Services. Common Terminology Criteria for Adverse. Events: CTCAE. V5.0. U.S. National Institutes of Health National Cancer Institute. https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/CTCAE_v5_Quick_Reference_8.5x11.pdf (2017 accessed 01 October 2021)."},{"key":"e_1_3_2_26_2","article-title":"Evaluation of the efficacy of ursodiol for prevention of hepatotoxicity in patients receiving gemtuzumab ozogamicin and inotuzumab ozogamicin","volume":"29","author":"Sabatino D","year":"2022","unstructured":"Sabatino D, Henneman A, Ahmad S, et al. Evaluation of the efficacy of ursodiol for prevention of hepatotoxicity in patients receiving gemtuzumab ozogamicin and inotuzumab ozogamicin. J Oncol Pharm Pract 2022; 29: 840\u2013839.","journal-title":"J Oncol Pharm Pract"}],"container-title":["Journal of Oncology Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552241313473","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10781552241313473","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552241313473","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T21:50:37Z","timestamp":1782251437000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10781552241313473"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,17]]},"references-count":25,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["10.1177\/10781552241313473"],"URL":"https:\/\/doi.org\/10.1177\/10781552241313473","relation":{},"ISSN":["1078-1552","1477-092X"],"issn-type":[{"value":"1078-1552","type":"print"},{"value":"1477-092X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,17]]}}}